Drug Patent Extended While FDA Review Drags On
Published Date: 7/23/2026
Notice
Summary
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means they keep exclusive rights to the drug until July 25, 2027, giving them more time to sell it without competition. This extension helps the company protect their investment while the drug gets final approval.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
One-Year Patent Extension for Centanafadine
Otsuka America Pharmaceutical was granted a one-year interim extension of U.S. Patent No. 8,461,196 for the drug centanafadine hydrochloride. The patent's term is extended from its original expiration date of July 25, 2026 through July 25, 2027 because the FDA regulatory review period is ongoing.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14939, Grant of Interim Extension of the Term of U.S. Patent No. 8,877,798; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means their patent, which was set to expire on July 25, 2026, now lasts until July 25, 2027. This extension helps Otsuka keep exclusive rights to their drug a bit longer while waiting for final FDA approval.
2026-14793, Requirement To Identify All Real Parties in Interest to a Third Party Request for an Ex Parte Reexamination
The USPTO wants anyone asking for a third-party ex parte reexamination to clearly say who’s really behind the request. This helps stop sneaky tricks and keeps the process honest. If you’re involved, get ready to share this info confidentially by August 21, 2026, or risk delays or issues.
2026-14388, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Admission to Practice and Roster of Registered Patent Attorneys and Agents Admitted to Practice Before the United States Patent and Trademark Office
The USPTO is asking for public feedback on its paperwork rules for patent attorneys and agents who want to practice before the office. This helps keep the process smooth and fair without making people fill out too many forms. If you have thoughts, send them in by August 17, 2026—no fees or big changes are happening right now, just a review.
2026-14389, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Response to Office Action and Voluntary Amendment Forms
The USPTO is asking for public feedback on updating forms used to respond to trademark office actions and make voluntary changes. This affects anyone applying for or managing trademarks and could streamline the process without extra costs. Comments are open until September 15, 2026, so don’t miss your chance to weigh in!
2026-14239, Electronic Filing Systems for Filings Pursuant to the Protocol Relating to the Madrid Agreement Concerning the International Registration of Marks
Starting July 31, 2026, U.S. trademark applicants can use the new Madrid e-Filing system to submit international trademark applications and fix issues faster. This system, run by WIPO and approved by the USPTO, makes filing smoother and lets the USPTO communicate directly with applicants to help correct problems. If you file trademarks internationally, get ready for a quicker, easier process—no extra fees announced yet!
2026-14240, References to Electronic Filing Systems in Rules of Practice in Filings Pursuant to the Protocol Relating to the Madrid Agreement Concerning the International Registration of Marks
The USPTO is updating its rules to swap out specific electronic filing system names with more general terms for submitting international trademark applications under the Madrid Protocol. This change won’t affect how you file or any fees—it just makes the language clearer and easier to follow. The new rule kicks in on July 15, 2026, and applies to anyone filing international trademark paperwork from the U.S.
Previous / Next Documents
Previous: 2026-14940, Grant of Interim Extension of the Term of U.S. Patent No. 9,737,506; Centanafadine Hydrochloride
Otsuka America Pharmaceutical just scored a one-year extension on their U.S. Patent for centanafadine hydrochloride, keeping their exclusive rights until July 25, 2027. This extra time helps them while the FDA finishes reviewing the drug for commercial use. Basically, Otsuka gets more runway to protect their invention and potentially make more money before others can copy it.
Next: 2026-14944, Land Between the Lakes Advisory Board
The Land Between the Lakes Advisory Board is holding a public meeting on September 16, 2026, to discuss plans for recreation, environmental education, and forest management in the area. Anyone interested can join in person or online and share their thoughts by September 11. This meeting helps shape how the land is cared for and enjoyed, with no new costs announced.